Pan American Silver Corp. (PAAS) Releases 2024 Sustainability Report
A man, dressed in protective gear, holding a golden nugget freshly extracted from an underground mining shaft.
On May 30, 2025, Pan American Silver Corp. (NYSE:PAAS) released its 2024 Sustainability Report, reporting a reduction of 220,000 cubic meters in its water use and a reduction in greenhouse gas emissions that exceeded targets. The company aims to reduce its Scope 1 and 2 emissions by 30% by 2030. The company also made progress in its social impact by investing $20.3 million in community initiatives, launching new economic programs, and increasing female hiring by 23%.
Looking ahead, the company's future outlook remains strong, with CIBC raising its price target on July 15, 2025, from $39 to $46, maintaining an 'Outperform' rating.
Pan American Silver Corp. (NYSE:PAAS) operates in Canada, Mexico, Peru, Bolivia, Argentina, Chile, and Brazil, exploring for silver, gold, zinc, lead, and copper deposits. It is included in our list of the best gold stocks.
While we acknowledge the potential of PAAS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 11 Most Undervalued Cloud Stocks Under $10 According to Hedge Funds and 11 Best Mineral Stocks to Buy According to Hedge Funds.
Disclosure: None.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
15 minutes ago
- New York Post
Senate makes progress in averting a gov't shutdown much earlier than usual
The Senate took a significant step towards averting an impending partial government shutdown by passing a tranche of funding bills much earlier than usual. Senators approved three of the 12 appropriations bills Friday needed to forestall a partial shutdown, including ones to fund the Department of Veterans Affairs, the Food and Drug Administration, the Department of Agriculture, new military facilities, and Congress itself. 'We are on the verge of an accomplishment that we have not done since 2018, and that is, pass appropriations bills across the Senate floor prior to the August recess,' Senate Appropriations Committee Chairwoman Susan Collins (R–Maine) cheered before the upper chamber reached the feat. 'That is exercising our constitutional responsibility for the power of the purse.' The three appropriations bills that clear the Senate are typically viewed as the less controversial ones to get across the finish line. Still, it comes amid significant hurdles toward preventing the looming autumn shutdown. 4 Sen. Susan Collins helped broker the deal to get the three appropriations bills passed through the Senate. REUTERS 4 Senate Majority Leader John Thune has eaten into the August recess to clear up the upper chamber's lengthy to-do list. Democrats widely see the shutdown fight as a rare instance in which they have leverage in Congress and have been vexed by President Trump's use of impoundment and rescissions to make spending cuts without their approval. Moreover, Congress hasn't actually passed the 12 appropriations bills to properly fund the government on time since 1997. Each fiscal year, which starts on Oct. 1, Congress is tasked with funding the government to prevent a partial shutdown. Congress has typically relied on a mechanism known as continuing resolutions, or CRs, to put government spending on autopilot for stretches of time. CRs and appropriations bills are subject to the 60-vote threshold needed to break a filibuster in the Senate and must be bipartisan, which is why Congress typically struggles with the process. 4 Sen. Patty Murray said the deal will help prevent some of the cuts Democrats opposed. The current fiscal year is running on what turned into a yearlong CR, and there have been some murmurs in the House about doing so again for Fiscal Year 2026. Senators voted 87-9 on Friday for a two-bill minibus to fund the VA and Department of Agriculture. They then voted 81–15 on the third appropriations bill to fund Congress. Sen. Patty Murray (D-Wash.), the top Democratic appropriator, argued the small-scale deal 'rejects damaging cuts from Trump and House Republicans,' despite progressive complaints. The Senate still has nine more appropriations bills to take up: Commerce, Defense, Energy, Financial Services, Homeland Security, Interior, Labor, State and Transportation. The Senate Appropriations Committee has already approved about half of those, inching them closer to a full chamber vote. 4 Oftentimes, government shutdown fights come down to the wire. REUTERS Those appropriations bills will need to be green-lit by the House of Representatives, which is on August recess, and signed into law by President Trump. Senate Majority Leader John Thune (R-SD) has eaten into the August recess while seeking to wrangle through key Trump nominations and chip away at the backlog. He is currently negotiating with Democrats on a deal to expedite that process.
TechCrunch
15 minutes ago
- TechCrunch
Anthropic cuts off OpenAI's access to its Claude models
In Brief Anthropic has revoked OpenAI's access to its Claude family of AI models, according to a report in Wired. Sources told Wired that OpenAI was connecting Claude to internal tools that allowed the company to compare Claude's performance to its own models in categories like coding, writing, and safety. TechCrunch has reached out to Anthropic and OpenAI for comment. In a statement to Wired, an Anthropic spokesperson said, 'OpenAI's own technical staff were also using our coding tools ahead of the launch of GPT-5,' which is apparently 'a direct violation of our terms of service.' (Anthropic's commercial terms forbid companies from using Claude to build competing services.) Meanwhile, an OpenAI spokesperson said, 'While we respect Anthropic's decision to cut off our API access, it's disappointing considering our API remains available to them.' Anthropic executives had already shown resistance to providing access to competitors, with Chief Science Officer Jared Kaplan previously justifying the company's decision to cut off Windsurf (a rumored OpenAI acquisition target, subsequently acquired by Cognition) by saying, 'I think it would be odd for us to be selling Claude to OpenAI.'
Business Insider
27 minutes ago
- Business Insider
Oppenheimer Predicts Up to 590% Rally for These 2 ‘Strong Buy' Stocks
There's a lot to say about the economy and markets today. Earnings season is well underway, with 317 S&P 500 companies having reported so far, and the results have been broadly encouraging – 83% have topped profit forecasts. That strength has helped drive both the S&P 500 and NASDAQ toward record highs, although August began with a pullback as investors reacted to a weaker-than-expected jobs report and the rollout of new tariffs from President Trump. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Even with those headwinds, Oppenheimer's chief investment strategist John Stoltzfus remains optimistic about the path ahead. 'This year reminds us of the classic Charles Dickens quote, 'It was the best of times, it was the worst of times.' Although much uncertainty and worry prevailed for some time both with trade policy and geopolitical events, and given the multitude of potential outcomes, we'd note that cooler heads prevailed – leading to positive outcomes at least for now. Monetary policy by the Fed has brought down the pace of inflation (if not yet to its 2% target level) without thus far causing a recession. This in our view is a substantial achievement… We are revising our year-end price target for the S&P 500 to 7,100 from 5,950,' Stoltzfus noted. That S&P target implies a gain of ~14% from current levels, a solid gain by any standard. But some stocks are going to outperform, even substantially – and Oppenheimer analysts are predicting much stronger rallies for 2 names in particular, including one with a potential upside as high as 590%. Using the TipRanks database, we've looked at the big-picture view on both of these picks, and it seems the broader Street agrees with Oppenheimer's bullish stance – both stocks hold Strong Buy consensus ratings, with forecasts pointing to potential triple-digit gains. Let's dig into what makes these high-upside picks so compelling. Climb Bio (CLYM) We'll start with Climb Bio, a biotech research firm focused on developing new treatments for immune-mediated diseases. These conditions – affecting an estimated 1 in 7 people worldwide – often stem from malfunctioning B cells, which can mistakenly attack the body's own tissues. Climb is developing therapies that target this root cause, aiming to address a range of serious and underserved diseases. The company's pipeline includes two drug candidates: its lead program, budoprutug, is currently being tested in three clinical trials and one preclinical study, while its second candidate, CLYM116, remains in preclinical development. Budoprutug is an anti-CD19 monoclonal antibody designed to deplete B cells. The drug has shown encouraging early clinical data and is now being evaluated in clinical trials across three distinct indications: primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE). In pMN, a rare autoimmune kidney disorder that causes damaging protein leakage into the urine, budoprutug is entering a Phase 2 open-label, dose-ranging trial to assess safety and efficacy. This follows positive data from a small Phase 1b study, in which 3 of 5 patients who completed all four doses achieved complete remission of proteinuria. All five patients in that study experienced rapid and sustained B-cell depletion, even at the lowest tested dose of 100 mg, and no serious drug-related adverse events were reported. Meanwhile, in ITP, Climb has received FDA clearance to begin a Phase 1b/2a study, with the trial now advancing. ITP is an autoimmune disorder in which B cells produce antibodies that target and destroy platelets. Budoprutug is being tested in this setting based on its CD19-targeting mechanism, which may offer an advantage over CD20-based therapies by depleting a broader range of B-cell populations, including plasma cells that drive the underlying disease process. The drug is also being explored in SLE, a chronic autoimmune disease that can cause widespread inflammation and tissue damage across multiple organs. A Phase 1b trial has been cleared by the FDA and is set to run at ex-U.S. sites. This open-label study is designed to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and early signs of clinical efficacy. Climb's B-cell-targeted approach is supported by the well-established role these cells play in driving lupus pathogenesis. To further expand its reach, Climb is also developing a subcutaneous formulation of budoprutug, with a Phase 1 trial in healthy volunteers expected to begin by year-end. Beyond budoprutug, Climb is advancing its second candidate, CLYM116, an Fc-engineered anti-APRIL monoclonal antibody with a novel pH-dependent mechanism. Currently in preclinical development, CLYM116 is being explored as a treatment for IgA nephropathy (IgAN), a serious kidney disorder also known as Berger's disease. Climb expects to report preclinical data and submit an Investigational New Drug (IND) application or Clinical Trial Application (CTA) by year-end. With CLYM trading at $1.45, Oppenheimer analyst Leland Gershell views the stock as a high-potential opportunity, pointing to the company's advancing clinical pipeline and the therapeutic promise of budoprutug. 'We have a favorable outlook on budoprutug across its three indications in primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE)… Each of these indications has clear IgG-driven pathophysiology and significant residual unmet need, despite existing first- and second-line therapies, where budoprutug has opportunity to shine above… We see $1B+ sales potential across these indications, and a subcutaneous, potentially use-at-home version offers upside optionality… With shares reflecting little credit for the company's opportunities and cash runway into 2027, we see favorable risk-reward and encourage investors to build a position. We would expect positive results in pMN to generate considerable stock upside potential,' Gershell opined. So how much upside does Gershell see overall? The analyst rates CLYM an Outperform (i.e., Buy), with a $10 price target – implying a substantial 590% surge over the next year. (To watch Gershell's track record, click here) Supporting this optimistic outlook, CLYM has 3 recent analyst reviews on record – all unanimously positive – earning the stock a Strong Buy consensus rating. With an average price target of $9, analysts expect shares to be changing hands at ~521% premium over the next 12 months. (See CLYM stock forecast) Wave Life Sciences (WVE) The next Oppenheimer pick is Wave Life Sciences, a biotech company developing a lineup of RNA medicines through its proprietary platform, dubbed PRISM. RNA therapeutics represent a fast-growing frontier in biotechnology, and Wave is harnessing innovations in chemistry and human genetics to create targeted treatments for serious, genetically driven diseases that have historically lacked effective solutions. This ambitious vision is translating into a diverse clinical pipeline. Wave is advancing four distinct programs, each built on a separate RNA modality: WVE-006 uses RNA editing, WVE-007 employs RNA interference (RNAi), WVE-N531 leverages exon skipping, and WVE-003 utilizes allele-selective silencing. By tackling different mechanisms and indications, the company is positioning itself to address multiple areas of high unmet medical need. WVE-006 is a GalNAc-conjugated, subcutaneously delivered RNA editing oligonucleotide (AIMer) designed to treat alpha-1 antitrypsin deficiency (AATD), a genetic disorder affecting the lungs and liver. The drug is currently in the Phase 1b/2a RestorAATion-2 trial, with key clinical data from both the 200 mg single and multidose cohorts expected in the third quarter of 2025. Additional results from the 400 mg single-dose cohort are anticipated later this fall. Progress is also accelerating with WVE-007, an RNAi therapy targeting obesity. This GalNAc-siRNA candidate works by silencing the INHBE gene and has shown strong preclinical efficacy in reducing weight while preserving muscle mass. Following promising initial safety and pharmacodynamic results in Cohort 1, Wave expanded enrollment in Cohort 2 and expects data from the first two cohorts in Q4 2025, with high-dose cohort results to follow in early 2026. The third program, WVE-N531, is an exon-skipping oligonucleotide developed for Duchenne muscular dystrophy (DMD), a severe and progressive neuromuscular disorder. In a Phase 2 open-label trial, the therapy showed statistically significant and clinically meaningful improvements in Time-to-Rise, a key measure of functional strength. Wave plans to submit a New Drug Application (NDA) in 2026 to pursue accelerated approval. Rounding out the clinical pipeline is WVE-003, an allele-selective oligonucleotide designed for Huntington's disease (HD). This first-in-class candidate has demonstrated selective reduction of mutant huntingtin protein (mHTT) while preserving healthy wild-type HTT – an approach believed to protect neuronal function. A Phase 2/3 trial is in planning, with Wave aiming to submit an IND in the second half of 2025. This pipeline, and its potential for success, has caught the attention of Oppenheimer analyst Cheng Li, who writes: 'We think RNA medicine is poised to become an important therapeutic modality for future medicine, leveraging its unique target engagement mechanism compared to other modalities. The PRISM platform further enhances the potency, durability, tissue distribution, and pharmacological properties of oligonucleotides in a multimodal fashion… We are optimistic about WVE's four clinical programs, each having its own merits and collectively providing validation to the platform technology that propels a next wave of programs for high-value targets with differentiated approaches… We anticipate multiple meaningful clinical catalysts from WVE-006 for alpha1 antitrypsin deficiency (AATD) and WVE-007 for obesity, with current valuation offering a favorable risk/reward setup.' Reflecting this conviction, Li assigns WVE an Outperform (i.e., Buy) rating, along with a $24 price target that suggests shares could surge 178% over the next year. (To watch Li's track record, click here) Li's bullish stance is echoed across the Street. The stock has picked up 12 recent analyst reviews, supporting a Strong Buy consensus rating, with an 11-to-1 split favoring Buys over Holds. Shares currently trade at $8.63, and the average price target of $18.18 points to a potential upside of ~111% over the next 12 months. (See WVE stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
